Hepcidin Behavior in Patients With Obesity and Bariatric Surgery (HOBS)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Nele Steenackers, MSc
- Phone Number: 0032 016 34 49 13
- Email: nele.steenackers@kuleuven.be
Study Locations
-
-
-
Leuven, Belgium, 3000
- UZ Leuven
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- The patient has to be 18 years or older
- Written informed consent has to be obtained after being informed on all aspects of the study
- The patient has a BMI > 30 kg/m² OR There has to be at least one year between the primary RYGB and the participation in the study OR There has to be at least one year between the primary SG and the participation in the study
Exclusion Criteria:
- Patients younger than 18 years old
- Women who are pregnant or are breastfeeding
- Post-menopausal women, defined as at least 6 months of amenorrhea after the final menstrual period
- Inability to follow the procedures of the studies due to language problems
- Patients who have had more than one bariatric surgery
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Cross-Sectional
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients with obesity
In 100 patients with obesity, blood samples will be collected.
|
Blood sample collection
|
|
Patients with a Sleeve Gastrectomy
In 100 patients with a Sleeve Gastrectomy, blood samples will be collected.
|
Blood sample collection
|
|
Patients with a Roux-en-Y Gastric Bypass
In 100 patients with a Roux-en-Y Gastric Bypass, blood samples will be collected.
|
Blood sample collection
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Serum hepcidin concentration
Time Frame: Study visit 1 day
|
Serum hepcidin concentration
|
Study visit 1 day
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hemoglobin concentration
Time Frame: Study visit 1 day
|
Hemoglobin concentration
|
Study visit 1 day
|
|
Mean corpuscular volume
Time Frame: Study visit 1 day
|
Mean corpuscular volume
|
Study visit 1 day
|
|
Iron concentration
Time Frame: Study visit 1 day
|
Iron concentration
|
Study visit 1 day
|
|
Ferritin concentration
Time Frame: Study visit 1 day
|
Ferritin concentration
|
Study visit 1 day
|
|
Transferrin concentration
Time Frame: Study visit 1 day
|
Transferrin concentration
|
Study visit 1 day
|
|
Transferrin saturation
Time Frame: Study visit 1 day
|
Transferrin saturation
|
Study visit 1 day
|
|
C-reactive protein
Time Frame: Study visit 1 day
|
C-reactive protein
|
Study visit 1 day
|
|
Vitamin B12 concentration
Time Frame: Study visit 1 day
|
Vitamin B12 concentration
|
Study visit 1 day
|
|
Folate (RBC level)
Time Frame: Study visit 1 day
|
Folate (RBC level)
|
Study visit 1 day
|
|
Folate (serum level)
Time Frame: Study visit 1 day
|
Folate (serum level)
|
Study visit 1 day
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- S62085
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepcidin
-
NCT03073369WithdrawnChronic Kidney Diseases | Iron-deficiency | Anemia | CKD | Vitamin D | Hepcidin | Ergocalciferol
-
NCT04458662CompletedInflammation | Iron-deficiency | Iron Metabolism Disorders | Exercise Induced Muscle Damage | Exercise Induced Iron-deficiency | Regulation of Sex Hormones on Hepcidin | Regulation of Sex Hormones on Muscle Damage
-
NCT06875947Active, not recruitingInflammation | Pregnancy Complications | Iron Deficiency Anemia of Pregnancy | Hepcidin | Moringa Oleifera | Cytokines (IL-1, IL-6)
Clinical Trials on Blood sampling
-
NCT04025541RecruitingGlioma | Sarcoma | Cancer | Breast Cancer | Colon Cancer | Lung Cancers
-
NCT02711332Completed
-
NCT04907773Completed
-
NCT06891508Active, not recruiting
-
NCT03857997CompletedPatients With Intellectual Disabilities Without an Obvious Clinical Diagnosis | Patients With Normal Array CGH and Previous Negative Genetic Investigations (WES-solo or WES-trio)
-
NCT03788772CompletedSepsis | Acute Circulatory Failure
-
NCT02658513CompletedThyroid Carcinoma | Thyroid Cancer | Cancer of the Thyroid | Cancer of Thyroid
-
NCT04697407Completed
-
NCT03388034CompletedBordetella Pertussis, Whooping Cough